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In  recent  years  mucosal  healing  has  emerged  as  an  important  therapeutic  goal  for  patients  with  inﬂam-
matory  bowel  disease.  Growing  evidence  suggests  that  achieving  mucosal  healing  can  improve  patient
outcomes  and,  potentially,  alter  the  course  of the  disease.  Drugs  currently  used  in the  management
of  inﬂammatory  bowel  disease  are  potentially  able  of  inducing  and  maintaining  mucosal  healing,  but
the  effect  size  is  difﬁcult  to  assess  because  of different  deﬁnitions  of  mucosal  healing,  differences  in
study  designs,  and  timing  of  endoscopic  evaluation.  Mucosal  healing  has  been  studied  extensively  in  the
biologic  era.  Data  available  from  different  sources,  such  as  controlled  trials  and  observational  studies,
show  that anti-TNF  therapies  can  induce  rapid  and  sustained  mucosal  healing  in  a  variable  percent-
age  of  patients  with  Crohn’s  disease  and  ulcerative  colits.  No  controlled  study  has  been  designed  to
identify  possible  predictors  of  mucosal  healing.  Some  clinical  characteristics  such  as  extensive  disease,
young  age  at  diagnosis,  and  smoking  status  may  be predictive  of  a more  aggressive  clinical  course  and,
presumably,  of  a  reduced  clinical  and  endoscopic  response  to  therapy.  Changes  and  normalization  of
C-reactive  protein  and  faecal  calprotectin  may  be  useful  tools  to  predict  outcomes,  guide  the  timing
for  endoscopic  evaluation  and,  possibly,  reduce  the  need  of  endoscopic  evaluation  in assessing  mucosal
healing.
© 2013 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica
 Italiana S.r.l. Open access under CC BY-NC-ND license.. Introduction
Since the 1960s, clinical studies suggested that in ulcerative
olitis (UC) patients the long-term outcome after a steroid course
as more favourable in patients who achieved both clinical and
ndoscopic remission compared to those who achieved clinical
emission only [1]. Up to the late 1990s, other observational stud-
es reported the lack of a similar correlation in patients with
rohn’s disease (CD). In particular, these studies described the
bsence of a clear impact of healing of the mucosal lesions on
elapse rates in CD patients with steroid-induced clinical remission
2]. These observations led clinicians to limit their CD treatment
∗ Corresponding author at: Gastroenterology and Hepatology Unit, San Filippo
eri  Hospital, Via Martinotti 20, 00135 Rome, Italy. Tel.: +39 0 6 33063169.
E-mail  address: c.papi@sanﬁlipponeri.roma.it (C. Papi).
1 Authors with equal contributions.
590-8658 © 2013 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroent
ttp://dx.doi.org/10.1016/j.dld.2013.07.006focus to symptomatic remission, therefore abandoning the idea
that mucosal healing (MH) could affect the natural course of the
disease.
The attitude of clinicians towards MH  changed drastically when
anti-TNF drugs entered the clinical scenario of inﬂammatory
bowel disease (IBD). For the ﬁrst time, in fact, it was thought
possible to achieve rapid healing of mucosal lesions also in CD
[3]. Since then, the interest on MH  grew so much that nowa-
days there is a trend towards considering MH a clinically relevant
end point for both UC and CD treatment strategies. As a conse-
quence of this growing interest around MH,  some studies have
retrospectively investigated the importance and impact of MH  in
the pre-biologic era. In particular, a Norwegian population-based
cohort study showed that the presence of MH 1 year after the diag-
nosis of IBD predicted a signiﬁcant reduction in surgery rates in the
subsequent years [4].
In  recent years, several clinical trials have examined the ability
of various agents to heal the mucosa in CD and UC.  However, inter-
preting these studies can be difﬁcult given the differences in study
design, the lack of a standardized deﬁnition of MH and different
timing of endoscopic evaluation.
erologica Italiana S.r.l. Open access under CC BY-NC-ND license.
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.1. Aminosalicylates and MH
There are no data on aminosalicylates-induced MH  in CD. Pre-
umably, these drugs are not able to induce MH and, although well
olerated, their clinical efﬁcacy in the long-term treatment of CD
s lacking [5]. Conversely, several data prove the capacity of both
ral and rectal aminosalicylates of inducing MH in mild to moder-
tely active UC. Regarding topical 5-aminosalicylic acid (5-ASA), a
eta-analysis of 10 studies showed that 36% of patients receiving
opical 5-ASA for 2–6 weeks achieved endoscopic remission com-
ared to 17% of patients receiving placebo [6]. As far as oral 5-ASA
s concerned, the percentage of endoscopic remission reported in
everal studies ranges from 25% to 70%, although different 5-ASA
oses and formulations, different deﬁnitions of MH,  and different
ime points of endoscopic evaluation have been used [7–9]. In a
ecent meta-analysis involving 3977 patients treated with oral 5-
SA and 2513 patients treated with rectal 5-ASA, the overall rate of
H was 36.9% in patients receiving oral 5-ASA and 50.3% in patients
eceiving rectal 5-ASA [10].
From a recent revision of the ASCEND I and II trials comparing 2
ifferent 5-ASA doses for inducing remission in 391 patients with
ild to moderately active UC, it emerged that, after 6 weeks of
reatment, MH  (deﬁned as a Mayo sub-score of 0 or 1) was achieved
n 80% of patients receiving 5-ASA 4.8 g/day and in 68% of patients
eceiving 5-ASA 2.4 g/day (p = 0.012). When MH  was deﬁned more
trictly as a Mayo sub-score equal to 0, these rates dropped to 32%
nd 24%, respectively, with no statistical difference between the 2
oses [11].
Another attempt to quantify the efﬁcacy of aminosalicylates
reparations in inducing MH was made by combining the results
f 2 randomized, double-blind, placebo-controlled trials that tested
ulti matrix system (MMX)  mesalazine on 517 patients with mild
o moderately active UC [12]. Complete or partial MH  (deﬁned as
lcerative colitis-disease activity index, UCDAI ≤ 1) was  achieved
n 76% of patients receiving mesalazine MMX  4.8 g/day, 70% of
atients receiving mesalazine MMX  2.4 g/day, and 44% of patients
eceiving placebo (p < 0.05). Considering a more strict deﬁnition of
ndoscopic remission (UCDAI = 0) the corresponding ﬁgures were
2%, 32%, and 16%, respectively [12]. Results of these pooled anal-
ses are summarized in Fig. 1.
Recently, in a prospective observational study [13], 81 patients
ith mild to moderately active UC received 5-ASA 4 g/day orally
nd 2 g/day per rectum for 6 weeks. Sixty-one patients (75%)
chieved clinical remission whereas endoscopic activity was  still
resent in only 5 patients (8%). The cumulative rate of relapse at
 year was 23% in patients with clinical and endoscopic remission
nd 80% in patients without endoscopic remission (p < 0.0001).
.2. Corticosteroids and MH
It has been known for a long time that steroids, despite their
xcellent capacity to induce clinical remission, are not powerful
n inducing MH  in CD. An historical trial evaluated the endoscopic
tatus of 131 patients with ileocolonic CD and steroid-induced clin-
cal remission. Endoscopic examination revealed that, after steroid
reatment, only 29% of patients in clinical remission were also in
ndoscopic remission, while the remaining 71% had persistence of
ndoscopic activity [14]. Across the pre-biologic era, this pivotal
tudy reinforced the impression that MH  could not be reached in
D and therefore should not be pursued as an end point. Conversely,
n UC, an equally important historical trial published by Truelove
t al. in 1955 showed that steroids were capable of inducing nor-
alization or improvement of the endoscopic ﬁndings. Endoscopic
emission was reached in 30% of patients receiving steroids vs 10%Disease 45 (2013) 978– 985 979
of  patients receiving placebo (p = 0.02); endoscopic improvement
was observed in 22% vs 21% of patients, respectively, and no change
or worsening of endoscopic ﬁndings was found in 48% vs 68% of
patients, respectively [15].
Recently, a prospective trial conducted by Ardizzone et al. on 157
UC patients at their ﬁrst steroid course showed that approximately
35% of patients achieved both clinical and endoscopic remission,
25% of patients achieved clinical but not endoscopic remission,
while another 35% of patients failed to respond to steroids. In this
study the endoscopic activity was  evaluated by means of the Baron
score: endoscopic remission was  deﬁned as a Baron score equal to
0. The same patients were followed up for up to 60 months and the
Kaplan–Meier analysis revealed that patients with both clinical and
endoscopic remission had a better outcome compared to patients
with only clinical remission in terms of need of immunomodu-
lators, hospitalization, and surgery [16]. In conclusion, these data
from historical and recent studies suggest a different effect of cor-
ticosteroids on MH  induction and long-term outcome in UC and
CD.
2.3. Immunomodulators and MH
Azathioprine (AZA) is usually considered effective in inducing
MH in CD, even though it is well known that this drug takes a
long time to achieve its potential beneﬁts. However, evidence for
AZA-induced MH  in CD is very limited, deriving from 2 small retro-
spective studies [17,18]. The ﬁrst study included 15 patients with
post-operative recurrence of ileitis who  had been treated with AZA
for more than 6 months. MH  was  observed in approximately 40%
of patients after a median time of 18 months (17.9 ± 5.6 months)
[17]. In the second study 20 CD patients were treated with AZA for
at least 9 months and, after a median time of treatment of approx-
imately 2 years, 54% of patients showed healing of the mucosal
lesions located in the ileum and 70% of patients showed healing of
the colonic lesions [18].
In  a prospective study from the GETAID (Groupe d’Etudes
Thérapeutiques des Affections Inﬂammatoires Digestives),
designed to assess the long-term outcome after AZA with-
drawal in patients with CD in remission, 83 patients in clinical
remission under AZA for at least 42 months were randomized to
continue AZA or to receive placebo. The primary end point was the
relapse rate over 18 months. At baseline, a subgroup of 45 patients
underwent endoscopic evaluation. Complete MH,  strictly deﬁned
as a Crohn’s disease endoscopic index of severity (CDEIS) = 0, was
observed in only 16 of 45 patients (36%), whereas in patients with
endoscopic activity, despite stable clinical remission, ulcerations
were still present in 21 of 45 patients (47%) [19].
A prospective open study published by Mantzaris et al. in 2009
was conducted on 77 patients with steroid-dependent CD who
had achieved clinical remission with steroids. These patients were
randomized to receive either budesonide or AZA as maintenance
treatment for 1 year and endoscopic and histological activity were
assessed at baseline and at study end. On per protocol analysis, 83%
of AZA-treated patients achieved complete or near-complete MH
compared to 24% of budesonide-treated patients (p = 0.0001). On
intention-to-treat analysis, and considering only complete MH,  the
percentage of patients with AZA-induced MH was 58% [20].
In  the SONIC study [21], which compared AZA, inﬂiximab (IFX),
and the combination therapy in moderate to severe CD, MH was
a secondary end point and it was assessed in a subset of patients
who underwent endoscopy at baseline and at week 26. Only 16% of
patients receiving AZA monotherapy achieved complete MH.Results  of studies with AZA in CD evaluating MH are summarized
in Fig. 2.
Regarding UC, a randomized controlled trial (RCT) published
in 2006 by Ardizzone et al. compared AZA with 5-ASA for the
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elayed-release mesalazine and multi-matrix mesalazine.
reatment of steroid-dependent UC. On intention-to-treat analysis,
ZA induced clinical and endoscopic remission in 55% of patients
ompared to 19% in those using 5-ASA. The per protocol analysis
evealed that AZA induced MH  in almost 60% of patients compared
o 20% for 5-ASA. Endoscopic remission was deﬁned as a Baron
ndex 1 or 0 [22].
Data  on methotrexate (MTX) are extremely limited in both CD
nd UC. Few open label studies with small sample sizes, different
TX doses, and different treatment duration reported a percentage
f MH  of approximately 35% in CD [23,24] and up to 60% in UC [25].
.4. Anti-TNF  ˛ agents and MH
In the last 15 years, the advent of anti-TNF  agents, such as
FX and adalimumab (ADA), has offered new options in the man-
gement of IBD. Data available from different sources (subgroup
nalysis of RCTs, observational cohort studies, and, more recently,
CTs) that have considered MH  as primary or secondary end point,
how that anti-TNF therapies can induce rapid and sustained MH,
nd may  contribute to ﬁstula closure in a variable percentage of
atients.
Fig. 2. Percentage of mucosal healing reported in differented with oral aminosalicylates. Pooled analyses of randomized controlled trials of
In 1999 D’Haens et al. reported the endoscopic and histological
response to a single infusion of IFX at a dose of 5, 10, or 20 mg/kg,
or placebo, in 30 CD patients. Patients treated with IFX experienced
a signiﬁcant decrease in CDEIS, while patients in the placebo group
did not experience any endoscopic improvement [26].
In  the ACCENT I endoscopic sub-study, 99 patients out of the
573 randomized, underwent endoscopic evaluation at baseline and
at different time points during the 1-year study period. Scheduled
IFX every 8 weeks induced MH  in approximately 50% of patients
at week 54, and sustained MH  (at both week 10 and week 54) in
approximately 30% of patients. Episodic treatment had little or no
impact on mucosal lesions [27].
D’Haens et al. conducted an unblinded trial on newly diagnosed
CD patients and compared early combined immunosuppression
(IFX and AZA) to conventional management. The primary end
points were remission off steroids and no bowel resection at weeks
26 and 52. A subset of 49 patients, from the initially randomized
cohort of 133 patients, underwent colonoscopy at baseline and after
2 years of therapy. Ulcer regression at 104 weeks occurred in 73.1%
of patients receiving combined immunosuppression and in 30.4% of
patients receiving conventional step-up approach (p = 0.002) [28].
 studies addressing azathioprine in Crohn’s disease.
 Liver 
l
e
p
u
a
u
t
i
w
s
p
s
d
s
w
2
e
w
r
o
A
s
p
r
a
e
e
o
i
o
(
1
m
s
i
a
r
2
M
s
p
3
[
p
a
w
t
o
[
m
e
ﬁ
r
2
a
i
o
T
s
0
f
factor for the development of colorectal cancer in long-standingC. Papi et al. / Digestive and
The results of these endoscopic sub-studies are conﬁrmed in
arge observational studies performed in tertiary centres. In the
xperience of the University of Leuven, within a cohort of 614
atients with CD treated with IFX, a subgroup of 214 patients
nderwent endoscopic evaluation before receiving IFX and after
 median of 6.7 months. Complete MH  was deﬁned as absence of
lcerations at follow-up endoscopy in patients who had ulcera-
ions at baseline, and partial MH was deﬁned as clear endoscopic
mprovement but still with ulcerations. Complete or partial MH
as reached, respectively, in 45.4% and 22.4% of the patients who
howed an initial clinical response to IFX treatment [29]. Com-
lete or partial MH  similarly reduced the need of major abdominal
urgery in the subsequent years (14%) compared to patients who
id not reach MH  (38%) [29].
In the SONIC study [21], 508 adult patients with moderate to
evere CD were randomized to receive a 30-week treatment course
ith IFX (5 mg/kg at weeks 0, 2 and 6, and then every 8 weeks), AZA
.5 mg/kg, or a combination of the 2 drugs. MH  was a secondary
nd point and was assessed in a subset of 309 patients who under-
ent endoscopy at baseline and at week 26. Overall, 44% of patients
eceiving the combination therapy achieved MH,  compared to 30%
f patients receiving IFX monotherapy and 16% of patients receiving
ZA alone.
The  EXTEND trial assessed the efﬁcacy of ADA in moderate to
evere ileo-colonic CD, and was the ﬁrst trial to assess MH as a
rimary end-point [30]. One hundred and twenty-nine patients
eceived an induction dose of ADA (160 mg  at week 0 and 80 mg
t week 2) followed by either scheduled ADA maintenance (40 mg
very other week) or placebo. After 12 weeks MH,  deﬁned as
ndoscopic absence of mucosal ulcerations, was observed in 27.4%
f patients in the treatment arm and in 13.1% of those receiv-
ng placebo (p = 0.056). At week 52, MH was observed in 24.2%
f patients receiving ADA and none of those receiving placebo
p < 0.001).
The ACT 1 and ACT 2 trials investigated the role of IFX (5 and
0 mg/kg, induction and scheduled maintenance) vs placebo, in
oderate to severe UC [31]. MH  was deﬁned as a Mayo endoscopic
ub-score ≤ 1 and was a secondary outcome. At week 8, approx-
mately 60% of patients receiving IFX achieved MH  compared to
pproximately 30% of patients receiving placebo. At week 30 the
ates of MH were approximately 50% in the treatment arm and
5% in the placebo arm; at week 54 (only in the ACT 1 trial) the
H rates were 46% vs 18%, respectively [31]. Considering a more
trict deﬁnition of MH  (i.e. Mayo sub-score = 0) the percentage of
atients acheving MH  at weeks 8, 30 and 54 were 25%, 30%, and
3% in the IFX group and 8%, 10%, and 16% in the placebo group
31]. The SUCCESS trial compared IFX, AZA, or IFX plus AZA in
atients with moderate to severe UC: patients treated with IFX
lone or IFX plus AZA had a higher rate of MH  compared to patients
ho received AZA as monotherapy. It must be noticed, though,
hat the trial lasted only 16 weeks and this is a very short lapse
f time in order to investigate the effects of immunomodulators
32].
Very  recently, 2 studies evaluated the role of ADA vs placebo in
oderate to severe UC [33,34]. In both studies MH  was  a secondary
nd point and was deﬁned as a Mayo endoscopic sub-score ≤ 1. The
rst trial [33] lasted 8 weeks; 390 patients were randomized to
eceive either placebo or ADA (either 160/80 mg at weeks 0 and
, or 80/40 mg  at weeks 0 and 2, followed by 40 mg  at weeks 4
nd 6). At week 8, MH  was observed in 41.5% of patients receiv-
ng placebo, 37.7% of patients receiving ADA 80/40 mg  and 46.9%
f patients receiving ADA 160/80 mg  (not statistically signiﬁcant).
he second study [34] included 494 UC patients with moderate to
evere UC that were randomized to receive ADA (160 mg  at week
, 80 mg  at week 2, and then 40 mg  every other week) or placebo
or 52 weeks. Patients were assessed endoscopically at week 8 andDisease 45 (2013) 978– 985 981
52 and MH  was  deﬁned as Mayo endoscopic sub-score ≤ 1. At week
8, 41.1% of patients receiving ADA achieved MH compared to 31.7%
of patients receiving placebo (p = 0.03). The corresponding ﬁgures
at week 52 were 25% and 15.4%, respectively (p < 0.01) [34]. Curi-
ously, in both studies the percentage of patients achieving clinical
remission (the primary end point) was consistently lower than that
of MH.  In the study of Reinisch et al. [33], the remission rates at 8
weeks were 9.2% in the placebo group, 10.0% in the 80/40 mg  group,
and 18.5% in the 160/80 mg  group. In the study of Sandborn et al.
[34] only 16.5% of patients receiving ADA were in clinical remis-
sion at 8 weeks as compared to 9.3% of patients receiving placebo
(p = 0.019); the corresponding features at 52 weeks were 17.3% and
8.5%, respectively (p = 0.004). Studies on anti-TNF agents that have
evalutaed MH in CD and UC are summarized in Tables 1 and 2,
respectively.
2.5. Granulocyte–monocyte apheresis and MH
Granulocyte–monocyte apheresis (GMA) is a relatively new
therapy that has been proposed for the treatment of IBD, par-
ticularly UC. The main mechanism of action of GMA  consists in
a selective removal of cell populations involved in the induction
and perpetuation of intestinal inﬂammation in IBD. GMA  is highly
selective for granulocytes, monocytes, and macrophages, while the
lymphocyte and erythrocyte populations are almost unchanged.
The  clinical efﬁcacy of GMA  in the management of UC  is con-
troversial. Most studies are uncontrolled and have been performed
mainly in UC patients who do not respond to conventional phar-
macological treatment. A favourable response (complete or partial
remission) has been reported in 60–84% of patients treated [35].
However, a double-blind, sham-controlled trial in patients with
active moderate to severe UC failed to show any efﬁcacy of GMA  for
the induction of clinical response or remission [36]. A recent meta-
analysis of 7 RCTs shows that GMA  induces a clinical remission in a
higher proportion of UC patients as compared to conventional med-
ical therapy, mainly systemic corticosteroids, with a better safety
proﬁle [37].
In  studies addressing GMA, evaluation of efﬁcacy has been
primarily performed using clinical and/or laboratory parameters,
whereas MH  has been rarely considered. According to the few data
available, MH  can occur in approximately 25% of patients treated
with GMA  [38,39].
2.6.  Histological healing
Apart  from the difﬁculties in interpreting the results of studies
that have considered MH as a primary or secondary end point, there
are other relevant debated issues, ﬁrst of all whether histology
should be included in the evaluation of MH.  Although theoret-
ically appealing, the prognostic relevance of histological healing
has not been extensively evaluated. In CD it is unknown whether
histological healing can be achieved with current medications as
well as what is its impact on the disease course [40]. However,
some data suggest a correlation between endoscopic and histolog-
ical improvement in patients receiving scheduled IFX maintenance
[26,41]. The issue of histological healing is particularly relevant in
UC as microscopic inﬂammation without gross endoscopic lesions
is predictive of disease relapse in patients who are in clinical and
endoscopic remission [42,43]. Moreover, some studies indicate that
the persistence of microscopic inﬂammation is an independent riskUC [44,45]. Although the effect of different drugs on microscopic
inﬂammation in UC has not been extensively studied, histologi-
cal healing may  be, theoretically, the ultimate therapeutic goal in
UC.
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3. Predictive markers of MH
3.1. Prediction based on symptoms
In general there is a poor correlation between symptoms and
endoscopic ﬁndings in IBD. The lack of correlation between clinical
response and MH  is especially evident in CD. In a recent prospective
study using wireless capsule endoscopy, Alkiviadis et al. analysed
3 different variables of mucosal lesions in 40 patients with small-
bowel CD [46]. After 1 month of medical therapy, there was  no
signiﬁcant correlation between clinical remission and improve-
ment of mucosal lesions. In the ACT 1 and ACT 2 trials [31], the
authors reported that MH along the trial was 11–27% higher than
the percentage of clinical remission. Finally, there is presumably a
time lag between symptoms improvement and MH  as the reverse is
true. In the evaluation of post-surgical recurrence, 73% of patients
displayed endoscopic lesions, but only 20% were symptomatic [47].
3.2. Prediction based on disease course
In CD patients, extensive small bowel disease, severe upper
gastrointestinal disease, rectal and perianal lesions, early stric-
turing/penetrating disease and deep ulcers are considered bad
prognostic factors. Moreover, smoking and young age at diagno-
sis are worsening factors [48]. In UC patients, extensive colitis,
severe colitis, need for systemic steroids at ﬁrst attack, and deep
ulcers are bad prognostic factors. Worsening factors are elevated
C-reactive protein (CRP) and stool frequency at third day of inten-
sive treatment and young age at diagnosis [49]. A Norwegian
population-based prospective study showed that education as
lifestyle, coping and adherence to treatment, and extensive disease
at diagnosis were signiﬁcant predictors of MH  for UC [4]. In the same
cohort, fever at diagnosis and treatment without steroids were sig-
niﬁcant predictors for MH  in CD. Unfortunately, no prospective
information is available.
3.3.  Prediction based on serum and faecal biomarkers
Inﬂammatory proteins are used to evaluate severity and activity
of inﬂammation and to monitor the response to therapy. The most
used acute phase protein is CRP, which is a highly sensitive acute
phase protein and an important non-invasive marker in IBD. CRP is
more sensitive in CD than in UC, although 20–25% of CD patients
do not have a CRP response in the acute phase [50,51].
A  recent study on 718 CD patients showed that a high CRP value
predicts response to biological therapy and that an early normaliza-
tion of CRP levels correlated with sustained long term response and,
presumably, MH  [52]. Kiss et al. recently analysed 210 consecutive
Hungarian patients with CD and showed that normalization of CRP
at week 12 is one of the strongest predictors of clinical efﬁcacy and
MH during the ﬁrst year of ADA therapy [53].
IL-6 is a proinﬂammatory cytokine that stimulates the liver to
produce CRP. The serum level of IL-6 is increased in IBD patients,
correlates with Crohn’s disease activity index (CDAI), and is pre-
dictive of disease relapse [54]. In a prospective study on 164 CD
patients IL-6 and CRP concentrations correlated with endoscopic
disease activity [55].
In  several studies orosomucoid, a component of the glycopro-
tein fraction of the serum, has been shown to be the most sensitive
parameter in comparison with acute phase proteins. Together with
alpha2-globulin and erythrocyte sedimentation rate (ESR), it shows
a high probability (88%) of predicting disease recurrence [56].
Hence, these parameters might represent a prognostic laboratory
index for predicting MH,  but no data are yet available.
Faecal calprotectin (FCp) is a neutrophilic, calcium-binding pro-
tein that passes trough the intestinal mucosa practically unscathed,
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Table  2
Rate  of mucosal healing in studies addressing anti-TNF antibodies in Ulcerative colitis.
Author, year (Ref) n patients Treatment regimen Deﬁnition of MH % MH
Rutgeerts, 2005 ACT 1, ACT 2
[31]
728 Moderate to severe UC Scheduled  IFX 5 or 10 mg/kg every
8  weeks
Mayo endoscopic
subscore ≤ 1
Week 8 60.7% IFX
Placebo 32.3% Placebo
54 weeks (ACT 1) Week 30 50.6% IFX
30 weeks (ACT 2) 27.4% Placebo
Week  54 (ACT 1) 46.0% IFX
18.2% Placebo
Panaccione,  2011 [32] UC
SUCCESS TRIAL
239 Moderate to severe
UC
AZA  2.5 mg/kg Mayo  endoscopic
subscore ≤ 1
Week 16 37% AZA
IFX 5 mg/kg 55% IFX
IFX 5 mg/kg + AZA 2.5 mg/kg 63% AZA + IFX
16 weeks
Reinisch,  2011 [33] 390 Moderate to severe
UC
ADA  160/80 mg or 80/40 mg at
weeks  0 and 2
Mayo endoscopic
subscore ≤ 1
Week 8 160/80 46.9% ADA
followed by 40 mg  at weeks 4 and 6 80/40 37.7% ADA
Placebo 41.5% Placebo
8 weeks
Sandborn,  2012 [34] 494  Moderate to severe
UC
ADA  160/80 mg and then 40 mg
eow
Mayo Endoscopic
subscore ≤ 1
Week 8 41.1% ADA
Placebo 31.7% Placebo
52 weeks Week 52 25.0% ADA
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nd remains stable for about 7 days at room temperature. FCp has
een found to be a sensitive marker of intestinal inﬂammation in
atients with IBD, useful in distinguishing inﬂammatory from non-
nﬂammatory bowel disorders [57]. A correlation has been found
etween FCp levels and endoscopic activity in CD, but not with
DAI. FCp and lactoferrin closely correlate with endoscopic disease
ctivity in UC [58] and also with CDEIS in CD, thus suggesting a
romising role as non-invasive surrogate markers for MH [59]. A
ormal FCp level in IBD in remission seems to predict MH  [60].
n a recent study Sipponem et al. investigated 15 patients with
everely active CD undergoing anti-TNF therapy. Endoscopy was
erformed at weeks 0 and 12. Five patients had MH  and 11 had
ndoscopic improvement at week 12. In patients with MH  the FCp
nd lactoferrin concentration dropped signiﬁcantly [61].
A  prospective multicentre large study was aimed at compar-
ng the ability of 4 different faecal markers of predicting steroid
efractoriness in severe paediatric UC [62]. One hundred and one
atients were enrolled and FCp, lactoferrin, M2-pyruvate kinase
M2-PK) and S-100A12 were dosed at baseline. M2-PK was  numer-
cally superior to the other 3 markers and to CRP in predicting
esponse to corticosteroid treatment; however, no information
bout MH  prediction is available.
.4. Prediction of MH  based on genetic factors
Genetic predisposition has an important role in many com-
lex diseases, including IBD; unfortunately, few and weak data
re available to correlate genetic “signature” and response to ther-
py. Many studies are in progress but the retrospective design
nd the non-homogeneous nature of recording are relevant lim-
tations. In 2 cohorts of patients with UC, RNA expression was
ompared in pre-treatment colonic mucosal biopsies between
esponders and nonresponders to IFX. Responders showed 5
ifferently expressed genes with a 95% sensitivity and 85%
peciﬁcity. These genes were: osteoprotegerin, stanniocalcin-1,
rostaglandin-endoperoxide synthase 2, IL-13 receptor alpha2, and
L-11 [63]. The same authors compared RNA expression in pre-
reatment colonic mucosal biopsies of patients with CD undergoing
FX therapy [64]. They were able to identify 5 differently expressed
enes in responders. These genes were: TNFAIP6 (hialoronan bind-
ng protein), S100A8, S100A9 (calcium binding protein), IL-11, and15.4% Placebo
GOS2 (lymphocyte cell cycle regulation). Given the good correla-
tion between response to IFX and MH,  it is conceivable that these
markers might also predict MH,  however, conﬁrmatory studies are
needed.
3.5. Prediction based on non-invasive imaging
The most commonly used imaging techniques in IBD are
ultrasonography (US), computed tomography (CT) and magnetic
resonance imaging (MRI). Bowel US has emerged as a low-cost, non-
invasive technique in the diagnosis and follow-up of patients with
CD. In a recent study on assessment of severity of post-operative
CD by US, wall thickness of ileo-colonic anastomosis (>3.5 mm)
identiﬁed 100% of patients with endoscopic lesions 6 months after
surgery and severe Rutgeerts score [65]. In UC, a variable concord-
ance has been found over time between endoscopic and clinical
score, with high and consistent concordance between endoscopic
and US score [66].
The  use of MRI  for assessment of CD is actually expanding and
there are many reports about MRI  and abdominal inﬂammatory
diseases. Rimola et al. in a recent study on CD aimed at deﬁn-
ing and validating a quantitative index of activity and severity
based on Magnetic Resonance Index of Activity (MaRIA). Twenty-
nine patients with clinically active disease and 19 with clinically
inactive disease underwent ileocolonoscopy and MRI. Endoscopic
activity was  evaluated with CDEIS. Wall thickness, relative contrast
enhancement, presence of oedema and ulcers on MRI  were found
as predictors of disease severity [67]. More studies are needed to
investigate whether non-invasive imaging might accurately predict
MH,  thus reducing the need for endoscopy and avoiding unneces-
sary endoscopic evaluations.
4.  Conclusions
Several drugs currently used in the management of CD and UC
are capable of inducing MH  but the effect size of different therapies
is difﬁcult to assess because of different deﬁnitions of MH,  differ-
ent study designs, and different timing of endoscopic evaluation.
In addition, especially in CD, data are obtained by sub-group and
post hoc analysis. The available evidence in UC suggests that corti-
costeroids are able to induce MH in the short term, and both oral
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nd topical 5-ASA compounds can induce and maintain MH in mild
o moderate disease. In more severe disease, immunosuppressive
rugs and biologic agents are proven to induce and maintain MH.
n CD, no data are available concerning 5-ASA; corticosteroids can
nduce MH  in the short term in a small percentage of patients, while
mmunosuppressive drugs and biological agents can induce and
aintain MH  in a variable proportion of patients. More importantly,
t has been recently found that thiopurines and anti-TNF agents
ay have a synergic effect not only on symptoms’ improvement
ut also in MH.  Unfortunately, no controlled prospective trials have
een designed so far to identify predictors of MH,  although this is
ighly desirable given the cost of biological therapy. While waiting
or this information, some clinical characteristics are predictive of
 more aggressive course and, presumably, can predict a reduced
linical and endoscopic response to therapy. The changes and nor-
alization of CRP and FCp are already useful tools to predict MH,  to
uide the timing for endoscopic evaluation, and, possibly, to reduce
he need of endoscopic evaluation in assessing MH. Thus the clini-
al dilemma remains with regard to which strategy to apply in CD
atients with complete relief of symptoms and normal biomarkers
ut persisting endoscopic activity. Ongoing clinical trials such as
ALM and ADACAL (www.clinicaltrials.gov) will presumably help
nswering  these questions.
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